Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (802) 802
index medicus (484) 484
oncology (382) 382
female (350) 350
hematology (339) 339
male (326) 326
middle aged (297) 297
adult (294) 294
randomized controlled trials as topic (251) 251
randomized-trial (213) 213
treatment outcome (212) 212
aged (173) 173
transplantation (172) 172
cancer (164) 164
adolescent (152) 152
antineoplastic agents - therapeutic use (129) 129
care and treatment (129) 129
bone-marrow-transplantation (128) 128
immunology (127) 127
chronic myelogenous leukemia (115) 115
chemotherapy (109) 109
randomized trial (106) 106
leukemia (105) 105
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (104) 104
research (104) 104
randomized controlled-trial (100) 100
risk factors (100) 100
medicine & public health (98) 98
therapy (94) 94
chronic myeloid-leukemia (93) 93
retrospective studies (91) 91
child (88) 88
animals (87) 87
transplantation, homologous (86) 86
stem-cell transplantation (85) 85
pharmacology & pharmacy (84) 84
imatinib mesylate (82) 82
survival (81) 81
health aspects (79) 79
protein kinase inhibitors - therapeutic use (79) 79
prognosis (78) 78
survival analysis (76) 76
stem cells (75) 75
antineoplastic combined chemotherapy protocols - therapeutic use (74) 74
young adult (74) 74
disease-free survival (73) 73
versus-host-disease (73) 73
hematology, oncology and palliative medicine (72) 72
chronic myeloid leukemia (71) 71
clinical trials (69) 69
clinical trials as topic (68) 68
hematopoietic stem cells (68) 68
survival rate (65) 65
acute myeloid-leukemia (64) 64
imatinib (64) 64
pyrimidines - therapeutic use (64) 64
follow-up studies (63) 63
analysis (62) 62
bone marrow transplantation (61) 61
hematopoietic stem cell transplantation - adverse effects (61) 61
acute lymphoblastic-leukemia (58) 58
benzamides (58) 58
drug therapy (58) 58
hematopoietic stem cell transplantation (58) 58
follow-up (56) 56
graft vs host disease - prevention & control (56) 56
bone-marrow transplantation (55) 55
transplantation conditioning - methods (55) 55
article (54) 54
child, preschool (53) 53
leukemia, myelogenous, chronic, bcr-abl positive - mortality (53) 53
neoplasms - drug therapy (53) 53
piperazines - therapeutic use (53) 53
dasatinib (52) 52
antineoplastic agents - administration & dosage (51) 51
antineoplastic agents - adverse effects (51) 51
mortality (51) 51
hematopoietic stem cell transplantation - methods (50) 50
total-body irradiation (50) 50
prospective studies (49) 49
aged, 80 and over (47) 47
recurrence (47) 47
stem cell transplantation (46) 46
acute disease (45) 45
leukemia, myelogenous, chronic, bcr-abl positive - therapy (45) 45
patients (45) 45
surgery (45) 45
bone marrow (44) 44
immunotherapy (44) 44
cell lung-cancer (41) 41
combined modality therapy (41) 41
hematologic neoplasms - therapy (41) 41
incidence (41) 41
prevention (41) 41
randomized phase-ii (41) 41
colony-stimulating factor (40) 40
graft vs host disease - etiology (40) 40
internal medicine (40) 40
time factors (40) 40
immunosuppressive agents - therapeutic use (39) 39
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: Long-term observation of 1151 patients from the randomized CML Study IV
by Fabarius, Alice and Leitner, Armin and Hochhaus, Andreas and Müller, Martin C and Hanfstein, Benjamin and Haferlach, Claudia and Göhring, Gudrun and Schlegelberger, Brigitte and Jotterand, Martine and Reiter, Andreas and Jung-Munkwitz, Susanne and Proetel, Ulrike and Schwaab, Juliana and Hofmann, Wolf-Karsten and Schubert, Jörg and Einsele, Hermann and Ho, Anthony D and Falge, Christiane and Kanz, Lothar and Neubauer, Andreas and Kneba, Michael and Stegelmann, Frank and Pfreundschuh, Michael and Waller, Cornelius F and Spiekermann, Karsten and Baerlocher, Gabriela M and Lauseker, Michael and Pfirrmann, Markus and Hasford, Joerg and Saussele, Susanne and Hehlmann, Rüdiger and German CML Study Grp and Schweizerische Arbeitsgemeinschaft and Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study Group and for the Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study Group
Blood, ISSN 0006-4971, 12/2011, Volume 118, Issue 26, pp. 6760 - 6768
The prognostic relevance of additional cytogenetic findings at diagnosis of chronic myeloid leukemia (CML) is unclear. The impact of additional cytogenetic... 
CHRONIC MYELOGENOUS LEUKEMIA | DERIVATIVE CHROMOSOME-9 DELETIONS | INTERFERON-ALPHA | Y-CHROMOSOME | PHILADELPHIA-CHROMOSOME | PHASE CML | BCR-ABL | CLONAL EVOLUTION | HEMATOLOGY | IMATINIB MESYLATE THERAPY | CHRONIC MYELOID-LEUKEMIA | Translocation, Genetic | Trisomy | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Young Adult | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis | Time Factors | Karyotyping | Aged, 80 and over | Adult | Female | Kaplan-Meier Estimate | Treatment Outcome | Disease Progression | Randomized Controlled Trials as Topic | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Chromosome Aberrations | Aged
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Is there a best TKI for chronic phase CML?
by Larson, Richard A
Blood, ISSN 0006-4971, 11/2015, Volume 126, Issue 21, pp. 2370 - 2375
The development of BCR/ABL1 tyrosine kinase inhibitors (TKIs) over the past 20 years has dramatically improved the outcomes for patients with every stage of... 
TRIAL | SURVIVAL | RANDOMIZED CML | SAFETY | FOLLOW-UP | DASATINIB | HEMATOLOGY | IMATINIB 400 MG | DEEP MOLECULAR RESPONSE | NILOTINIB | CHRONIC MYELOID-LEUKEMIA | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Fusion Proteins, bcr-abl - genetics | Animals | Protein Kinase Inhibitors - therapeutic use | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Fusion Proteins, bcr-abl - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Philadelphia Chromosome | Fusion Proteins, bcr-abl - metabolism | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text The argument for using imatinib in CML
by Claudiani, Simone and Claudiani, Simone and Apperley, Jane F and Apperley, Jane F
Hematology. American Society of Hematology. Education Program, ISSN 1520-4391, 11/2018, Volume 2018, Issue 1, pp. 161 - 167
June 2018 was the 20th anniversary of the clinical use of the first tyrosine kinase inhibitor (TKI), imatinib, for chronic myeloid leukemia. Since then, the... 
EARLY MOLECULAR RESPONSE | IMPACT | CHRONIC-PHASE | RANDOMIZED CML | FOLLOW-UP | TRANSCRIPT | DASATINIB | HEMATOLOGY | EDUCATION, SCIENTIFIC DISCIPLINES | INTERIM ANALYSIS | CHRONIC MYELOID-LEUKEMIA | FRONTLINE NILOTINIB | With Great Success Comes Great Responsibility | Chronic Myeloid Leukemia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Innovation in hematology. Perspectives: CML 2016
by Hehlmann, Rüdiger
Haematologica, ISSN 0390-6078, 05/2016, Volume 101, Issue 6, pp. 657 - 659
SURVIVAL | RANDOMIZED CML | INHIBITOR THERAPY | IMATINIB | MOLECULAR RESPONSE | HEMATOLOGY | CHRONIC MYELOID-LEUKEMIA | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy | Hematology - trends | Hematology - methods | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Humans
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Molecular monitoring in CML: how deep? How often? How should it influence therapy?
by Shanmuganathan, Naranie and Hughes, Timothy P
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue 20, pp. 2125 - 2133
With the advent of tyrosine kinase inhibitors (TKIs), the goals of therapy in chronic myeloid leukemia (CML) are steadily shifting. Long-term disease control... 
TYROSINE KINASE INHIBITORS | CHRONIC MYELOGENOUS LEUKEMIA | TREATMENT-FREE REMISSION | TREATMENT DISCONTINUATION | CHRONIC-PHASE | RANDOMIZED CML | HARMONIZING CURRENT METHODOLOGY | DOMAIN MUTATIONS | HEMATOLOGY | CHRONIC MYELOID-LEUKEMIA | BCR-ABL TRANSCRIPTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: Long-term observation in CML Study IV
by Miranda, M.B and Lauseker, M and Kraus, M.-P and Proetel, U and Hanfstein, B and Fabarius, A and Baerlocher, G.M and Heim, D and Hossfeld, D.K and Kolb, H.-J and Krause, S.W and Nerl, C and Brümmendorf, T.H and Verbeek, W and Fauser, A.A and Prümmer, O and Neben, K and Hess, U and Mahlberg, R and Plöger, C and Flasshove, M and Rendenbach, B and Hofmann, W.-K and Müller, M.C and Pfirrmann, M and Hochhaus, A and Hasford, J and Hehlmann, R and Saußele, S
Leukemia, ISSN 0887-6924, 06/2016, Volume 30, Issue 6, pp. 1255 - 1262
Treatment of chronic myeloid leukemia (CML) has been profoundly improved by the introduction of tyrosine kinase inhibitors (TKIs). Long-term survival with... 
TYROSINE KINASE INHIBITORS | SURVIVAL | 2ND CANCER-RISK | SOLID CANCERS | RANDOMIZED CML | ONCOLOGY | FOLLOW-UP | RADIOTHERAPY | ESSENTIAL THROMBOCYTHEMIA | HEMATOLOGY | CHEMOTHERAPY | TRANSPLANTATION | Lymphoma, Non-Hodgkin - chemically induced | Follow-Up Studies | Humans | Middle Aged | Interferon-alpha - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Protein Kinase Inhibitors - adverse effects | Colorectal Neoplasms - chemically induced | Incidence | Imatinib Mesylate - therapeutic use | Neoplasms, Second Primary - chemically induced | Protein Kinase Inhibitors - therapeutic use | Imatinib Mesylate - adverse effects | Sex Factors | Aged, 80 and over | Adult | Female | Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications | Oncology, Experimental | Development and progression | Disease susceptibility | Chronic myeloid leukemia | Research | Drug therapy | Cancer | Care and treatment | Interferon | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Another piece of the puzzle – optimal TKI selection before treatment discontinuation in CML
by Wolf, Dominik
European Journal of Haematology, ISSN 0902-4441, 03/2015, Volume 94, Issue 3, pp. 189 - 190
TRIAL | THERAPY | DASATINIB | HEMATOLOGY | IMATINIB | CHRONIC MYELOID-LEUKEMIA | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Dasatinib | Drug Administration Schedule | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Treatment Outcome | Antineoplastic Agents - therapeutic use | Piperazines - therapeutic use | Thiazoles - therapeutic use | Imatinib Mesylate | Remission Induction | Randomized Controlled Trials as Topic | Benzamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials
by Spiess, Birgit and Rinaldetti, Sébastien and Naumann, Nicole and Galuschek, Norbert and Kossak-Roth, Ute and Wuchter, Patrick and Tarnopolscaia, Irina and Rose, Diana and Voskanyan, Astghik and Fabarius, Alice and Hofmann, Wolf-Karsten and Saußele, Susanne and Seifarth, Wolfgang
PLoS ONE, ISSN 1932-6203, 03/2019, Volume 14, Issue 3, p. e0214305
In chronic myeloid leukemia (CML), the duration of deep molecular response (MR) before treatment cessation (MR4 or deeper, corresponding to BCR-ABL1 <= 0.01%... 
TREATMENT-FREE REMISSION | CONTROL GENES | TRANSCRIPTS | STANDARDIZATION | POLYMERASE-CHAIN-REACTION | RANDOMIZED CML | RESIDUAL DISEASE DETECTION | MULTIDISCIPLINARY SCIENCES | IMATINIB | MESSENGER-RNA QUANTIFICATION | CHRONIC MYELOID-LEUKEMIA | RNA sequencing | Medical research | Care and treatment | Usage | Prognosis | Analysis | Medicine, Experimental | Chronic myeloid leukemia | Genetic transcription | Sensitivity analysis | Hematology | Laboratories | Myeloid leukemia | Leukemia | Genes | Clinical trials | Reverse transcription | Oncology | Leukocytes (mononuclear) | Ribonucleic acid--RNA | Medical diagnosis | Patients | Ski protein | Polymerase chain reaction | Sensitivity | Hospitals | Quality control | Peripheral blood mononuclear cells | Remission | Sensitivity enhancement | Diagnostic systems | Monitoring | RNA | Ribonucleic acid
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML
by Fabarius, Alice and Kalmanti, Lida and Dietz, Christian T and Lauseker, Michael and Rinaldetti, Sébastien and Haferlach, Claudia and Göhring, Gudrun and Schlegelberger, Brigitte and Jotterand, Martine and Hanfstein, Benjamin and Seifarth, Wolfgang and Hänel, Mathias and Köhne, Claus-Henning and Lindemann, Hans W and Berdel, Wolfgang E and Staib, Peter and Müller, Martin C and Proetel, Ulrike and Balleisen, Leopold and Goebeler, Maria-Elisabeth and Dengler, Jolanta and Falge, Christiane and Kanz, Lothar and Burchert, Andreas and Kneba, Michael and Stegelmann, Frank and Pfreundschuh, Michael and Waller, Cornelius F and Spiekermann, Karsten and Brümmendorf, Tim H and Edinger, Matthias and Hofmann, Wolf-Karsten and Pfirrmann, Markus and Hasford, Joerg and Krause, Stefan and Hochhaus, Andreas and Saußele, Susanne and Hehlmann, Rüdiger and German CML Study Grp and SAKK and SAKK and the German CML Study Group and for the SAKK and the German CML Study Group
Annals of Hematology, ISSN 0939-5555, 12/2015, Volume 94, Issue 12, pp. 2015 - 2024
Major route additional cytogenetic aberrations (ACA) at diagnosis of chronic myeloid leukaemia (CML) indicate an increased risk of progression and shorter... 
Prognosis | Medicine & Public Health | Hematology | Outcome | Cytogenetics | Oncology | Chronic myeloid leukaemia | Balanced and unbalanced karyotypes | SURVIVAL | CLONAL EVOLUTION | CHRONIC MYELOID-LEUKEMIA | INTERFERON-ALPHA | RANDOMIZED CML | RECOMMENDATIONS | PHASE CML | CYTOGENETIC RESPONSE | ABERRATIONS | HEMATOLOGY | IMATINIB MESYLATE | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Survival Rate | Abnormal Karyotype | Disease-Free Survival | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis | Karyotyping | Adolescent | Aged, 80 and over | Adult | Female | Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Philadelphia Chromosome | Diagnosis | Chromosomes | Analysis | Leukemia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI
by Saglio, Giuseppe and Jabbour, Elias
Leukemia & Lymphoma, ISSN 1042-8194, 07/2018, Volume 59, Issue 7, pp. 1523 - 1538
Patients diagnosed with chronic myeloid leukemia (CML) and treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs) have long life spans. Selection of an... 
signaling therapies | myeloproliferative disorders | Myeloid leukemias and dysplasias | CHRONIC MYELOGENOUS LEUKEMIA | KINASE INHIBITOR OPTIMIZATION | FOLLOW-UP | IMATINIB TREATMENT | CHRONIC MYELOID-LEUKEMIA | 400 MG | INTERFERON-ALPHA | EUTOS SCORE | RANDOMIZED CML | ONCOLOGY | HEMATOLOGY | DEEP MOLECULAR RESPONSE | Drug Costs | Humans | Leukemia, Myeloid, Chronic-Phase - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Treatment Outcome | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Protein Kinase Inhibitors - administration & dosage | Medication Adherence | Antineoplastic Agents - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Leukemia, Myeloid, Chronic-Phase - metabolism | Leukemia, Myeloid, Chronic-Phase - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Molecular monitoring in CML: how deep? How often? How should it influence therapy?
by Shanmuganathan, Naranie and Shanmuganathan, Naranie and Hughes, Timothy P and Hughes, Timothy P
Hematology. American Society of Hematology. Education Program, ISSN 1520-4391, 11/2018, Volume 2018, Issue 1, pp. 168 - 176
With the advent of tyrosine kinase inhibitors (TKIs), the goals of therapy in chronic myeloid leukemia (CML) are steadily shifting. Long-term disease control... 
TYROSINE KINASE INHIBITORS | CHRONIC MYELOGENOUS LEUKEMIA | TREATMENT-FREE REMISSION | TREATMENT DISCONTINUATION | CHRONIC-PHASE | RANDOMIZED CML | HARMONIZING CURRENT METHODOLOGY | DOMAIN MUTATIONS | HEMATOLOGY | EDUCATION, SCIENTIFIC DISCIPLINES | CHRONIC MYELOID-LEUKEMIA | BCR-ABL TRANSCRIPTS | With Great Success Comes Great Responsibility | Chronic Myeloid Leukemia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Is there a best TKI for chronic phase CML?
by Larson, Richard A
Hematology, ISSN 1520-4391, 12/2015, Volume 2015, Issue 1, pp. 250 - 256
The development of BCR/ABL1 tyrosine kinase inhibitors (TKIs) over the past 20 years has dramatically improved the outcomes for patients with every stage of... 
TRIAL | SURVIVAL | RANDOMIZED CML | SAFETY | FOLLOW-UP | DASATINIB | HEMATOLOGY | IMATINIB 400 MG | EDUCATION, SCIENTIFIC DISCIPLINES | DEEP MOLECULAR RESPONSE | NILOTINIB | CHRONIC MYELOID-LEUKEMIA | Prognosis | Risk Assessment | Humans | Clinical Trials as Topic | Evidence-Based Medicine | Remission Induction | Disease Progression | Randomized Controlled Trials as Topic | Protein Kinase Inhibitors - therapeutic use | Quality of Life | Leukemia, Myeloid, Chronic-Phase - therapy | Fusion Proteins, bcr-abl - therapeutic use | Mutation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Second-generation tyrosine kinase inhibitors: The future of frontline CML therapy
by Kantarjian, Hagop M and Baccarani, Michele and Jabbour, Elias and Saglio, Giuseppe and Cortes, Jorge E
Clinical Cancer Research, ISSN 1078-0432, 04/2011, Volume 17, Issue 7, pp. 1674 - 1683
All available data from ongoing studies of second-generation tyrosine kinase inhibitors (TKIs) for treatment of patients with newly diagnosed chronic myeloid... 
CHRONIC MYELOGENOUS LEUKEMIA | CYTOGENETIC RESPONSES | ONCOLOGY | UP SUSTAINED SURVIVAL | IMATINIB | EARLY CHRONIC-PHASE | 800 MG | FOLLOW-UP | OPEN-LABEL | PATIENTS PTS | CHRONIC MYELOID-LEUKEMIA | Dasatinib | Aniline Compounds - pharmacology | Nitriles - pharmacology | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Treatment Outcome | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Pyrimidines - pharmacology | Thiazoles - therapeutic use | Quinolines - pharmacology | Randomized Controlled Trials as Topic | Pyrimidines - therapeutic use | Antineoplastic Agents - pharmacology | Quinolines - therapeutic use | Thiazoles - pharmacology | Aniline Compounds - therapeutic use | Nitriles - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Clonal evolution and blast crisis correlate with enhanced proteolytic activity of Separase in BCR-ABL b3a2 fusion type CML under imatinib therapy
by Haaß, Wiltrud and Kleiner, Helga and Weiß, Christel and Haferlach, Claudia and Schlegelberger, Brigitte and Müller, Martin C and Hehlmann, Rüdiger and Hofmann, Wolf-Karsten and Fabarius, Alice and Seifarth, Wolfgang and German Cml Study Grp and SAKK and Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung and German CML Study Group and Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study Group
PLoS ONE, ISSN 1932-6203, 06/2015, Volume 10, Issue 6, p. e0129648
Unbalanced (major route) additional cytogenetic aberrations (ACA) at diagnosis of chronic myeloid leukemia (CML) indicate an increased risk of progression and... 
CHRONIC MYELOGENOUS LEUKEMIA | TYROSINE KINASE INHIBITORS | RANDOMIZED CML | MULTIDISCIPLINARY SCIENCES | PHASE CML | EXPRESSION LEVELS | CENTROSOME ABERRATIONS | HUMAN CANCERS | CELL-LINE | CHRONIC MYELOID-LEUKEMIA | CHROMOSOMAL INSTABILITY | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Blast Crisis - pathology | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Antineoplastic Agents - therapeutic use | Blast Crisis - enzymology | Young Adult | Fusion Proteins, bcr-abl - genetics | Imatinib Mesylate - therapeutic use | Proteolysis | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Adolescent | Chromosome Aberrations | Aged, 80 and over | Cell Line, Tumor | Adult | Aged | Blast Crisis - genetics | Separase - metabolism | Chromosome Breakage | Clonal Evolution | Cysteine | Explosions | BCR protein | Therapy | Biotechnology | Mitosis | Hyperactivity | Leukemia | Aneuploidy | Kinases | Mimicry | Proteins | Protein folding | Cell cycle | Evolution | Blast crisis | Fusion protein | Imatinib | Separase | Myeloid leukemia | Abl protein | Chronic myeloid leukemia | Gene expression | Patients | Philadelphia chromosome | Endopeptidase | Medical prognosis | Cell lines | Mutation | Spindles | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights